- Home
- ENTX vs GCV Comparison
ENTX vs GCV Comparison
Compare ENTX & GCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- GCV
- Stock Information
- Founded
- ENTX 2010
- GCV 1988
- Country
- ENTX Israel
- GCV United States
- Employees
- ENTX N/A
- GCV N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- GCV Finance/Investors Services
- Sector
- ENTX Health Care
- GCV Finance
- Exchange
- ENTX Nasdaq
- GCV Nasdaq
- Market Cap
- ENTX 69.6M
- GCV 75.6M
- IPO Year
- ENTX 2018
- GCV N/A
- Fundamental
- Price
- ENTX $1.67
- GCV $3.73
- Analyst Decision
- ENTX Strong Buy
- GCV
- Analyst Count
- ENTX 1
- GCV 0
- Target Price
- ENTX $10.00
- GCV N/A
- AVG Volume (30 Days)
- ENTX 46.7K
- GCV 57.9K
- Earning Date
- ENTX 03-28-2025
- GCV 01-01-0001
- Dividend Yield
- ENTX N/A
- GCV 13.04%
- EPS Growth
- ENTX N/A
- GCV N/A
- EPS
- ENTX N/A
- GCV N/A
- Revenue
- ENTX $181,000.00
- GCV N/A
- Revenue This Year
- ENTX N/A
- GCV N/A
- Revenue Next Year
- ENTX N/A
- GCV N/A
- P/E Ratio
- ENTX N/A
- GCV N/A
- Revenue Growth
- ENTX N/A
- GCV N/A
- 52 Week Low
- ENTX $1.41
- GCV $3.15
- 52 Week High
- ENTX $3.35
- GCV $4.58
- Technical
- Relative Strength Index (RSI)
- ENTX 32.36
- GCV 39.29
- Support Level
- ENTX $1.85
- GCV $3.64
- Resistance Level
- ENTX $2.02
- GCV $3.86
- Average True Range (ATR)
- ENTX 0.11
- GCV 0.09
- MACD
- ENTX -0.01
- GCV -0.00
- Stochastic Oscillator
- ENTX 10.87
- GCV 34.62
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.